Recent Updates
Recently added Catalysts
PPBT

Purple Biotech Ltd. Consolidated Unaudited Statements of Financial Position as of: March 31 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 10,195 11,247 Short term deposits 45,258 46,5

Key Takeaway: Consolidated Unaudited Statements of Financial Position as of: March 31 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 10,195 11,247 Short term deposits 45,258 46,558 Trade receivables 500 500 Other curre

Full Press Release Details

Consolidated Unaudited Statements of Financial Position as of:
March 31 December 31
2021 2020
USD thousands USD thousands
Assets
Cash and cash equivalents 10,195 11,247
Short term deposits 45,258 46,558
Trade receivables 500 500
Other current assets 1,489 977
Total current assets 57,442 59,282
Non-current assets
Right to use assets 752 790
Fixed assets, net 207 178
Long term deposits 3,071 3,071
Intangible assets 20,482 20,482
Total assets 81,954 83,803
Liabilities
Lease liability - short term 207 207
Accounts payable 1,335 1,198
Other payables 4,431 1,693
Total current liabilities 5,973 3,098
Non-current liabilities
Lease liability 622 688
Post-employment benefit liabilities 265 265
Total non-current liabilities 887 953
Equity
Share capital, no par value - -
Share premium 122,077 118,909
Receipts on account of warrants 28,017 29,984
Capital reserve for share-based payments 8,825 8,115
Capital reserve from transactions with related parties 761 761
Capital reserve from transactions with non-controlling
interest (859 ) (859 )
Accumulated loss (84,068 ) (77,521 )
Equity attributable to owners of the Company 74,753 79,389
Non-controlling interests 341 363
Total equity 75,094 79,752
Total liabilities and equity 81,954 83,803
Consolidated Unaudited Statement of Operations for the period ended
March 31
2021
USD thousands
Revenues -
Research and development expenses 5,007
Sales, general and administrative expenses 1,665
Reimbursement of legal fees (5 )
Total operating expenses 6,667
Operating loss 6,667
Expenses (income) on account of warrants -
Finance expenses 20
Finance income (118 )
Finance expenses (income), net (98 )
Loss for the period 6,569
Loss attributable to:
Owners of the Company 6,547
Non-controlling interests 22
6,569
Loss per share data
Basic and diluted loss per ADS - USD 0.38
Number of shares used in calculating basic and diluted loss per ADS 17,377,241
Reconciliation of Adjusted Operating Loss
March 31
2021
USD thousands
Operating loss for the period 6,667
Less ESOP expenses (710 )
5,957
Last updated: Jun 9, 2021